カイロス時間：All Dogs Live in the Moment--飼い主と一緒なら、何歳からでも犬は変われる

CATEGORY

カイロス時間

［2018］犬の過敏症多動症候群に関するレトロスペクティブ研究：フルオキセチン大量投与の長期成績と臨床スコアの提案

Retrospective study on hypersensitivity-hyperactivity syndrome in dogs: long-term outcome of high dose fluoxetine treatment and proposal of a clinical score

書誌情報Masson, S. & Gaultier, E. Retrospective study on hypersensitivity-hyperactivity syndrome in dogs: Long-term outcome of high dose fluoxetine treatment and proposal of a clinical score. Dog Behav. 4, 15–35 (2018).
https://doi.org/10.4454/db.v4i2.79

Notice

表題の論文を日本語訳してみました。翻訳アプリにかけた日本語訳を英文に照らして修正していますが、表記のゆれや訳の間違いがあるかもしれません。正確に内容を知りたい方は、原文をご覧ください。

Abstract：要旨

In the French veterinary psychiatry model, the canine version of attention deficit hyperactivity disorder is called hypersensitivity-hyperactivity syndrome (HSHA) and it includes two stages, depending on the symptom severity.

フランスの獣医精神医学モデルでは、注意欠陥多動性障害の犬バージョンは過敏性多動症候群（HSHA）と呼ばれ、症状の重症度に応じて2つの段階がある。

Since methylphenidate is not authorized for veterinary use in France, HSHA dogs are commonly treated with 2 to 4 mg/kg fluoxetine associated with behavioural modifications.

フランスではメチルフェニデートは動物用医薬品として認可されていないため、HSHA犬には一般的に2～4mg/kgのフルオキセチンを投与し、行動学的な修正を加えている。

Thus, the aim of this study was to analyze the long-term outcome of this global approach. Twenty-four dogs diagnosed with HSHA were included.

したがって、この研究の目的は、このグローバルなアプローチの長期的転帰を分析することであった。HSHAと診断された24頭の犬を対象とした。

For each dog, 42 descriptive data were analyzed. Primary reasons for consulting were variable if the dogs had an additionnal behavioural diagnosis (i.e. 33% of the dogs): complaints were linked to the comorbid diagnosis (e.g. bite on strangers, people phobia), whereas they were linked to autocontrol deficiency for the dogs diagnosed with HSHA only (e.g. destructive, mouth, jumps on people).

それぞれの犬について、42の記述的データが分析された。主な受診理由は、行動学的診断が併存している犬（33％）については様々であった：愁訴は併存診断と関連していた（例：他人への咬みつき、対人恐怖症）のに対し、HSHAと診断された犬のみでは自制不全と関連していた（例：破壊的、口、人への飛びつき）。

HSHA affection deeply alters the dog-human bond, as severe cases often lead owners to think about euthanasia or rehoming (12% for stage 1, but 83% for stage 2).

HSHAの愛情は犬と人間の絆を深く変化させ、重症例では飼い主が安楽死や再飼育を考えるようになることが多い（ステージ1では12％、ステージ2では83％）。

Neither the possibility to have access to a garden nor the quantity of daily exercise were linked to HSHA stages (respectively, Fisher’s exact test, p=0.69, and Kruskal-Wallis, p=0.88).

庭を利用できる可能性も、毎日の運動量も、HSHAの病期とは関連していなかった（それぞれ、Fisherの正確検定、p=0.69、Kruskal-Wallis、p=0.88）。

Eighty-three percent of the dogs attended training classes before consulting, with no noticeable improvement (mean training improvement score 1.7/10). In addition, training seemed even less efficient on severe cases, i.e. stage 2 dogs (Kruskall-Wallis, p<0.03).

83％の犬が相談前にトレーニングクラスに参加したが、顕著な改善は見られなかった（平均トレーニング改善スコア1.7/10）。さらに、重症例、すなわちステージ2の犬では、トレーニングの効率はさらに低いようであった（Kruskall-Wallis、p<0.03）。

After two months of high dose fluoxetine (2 to 4 mg/kg), the average score of improvement given by owners was 7.2/10 compared to 0/10 at start. No long-term adverse effect was reported.

高用量のフルオキセチン（2～4mg/kg）を2ヵ月間投与した結果、飼い主の平均改善スコアは7.2/10であった（投与開始時は0/10）。長期的な副作用は報告されなかった。

A HSHA clinical score (0 to 5 scale) was built to better categorize the dogs and to conduct the follow-up. The HSHA clinical score was correlated to fluoxetine dose (Pearson correlation, p<0.01) and duration (Pearson correlation, p<0.05). A successful weaning from treatment was possible for 54% of the dogs.

HSHA臨床スコア（0〜5スケール）を作成し、犬の分類と経過観察を行った。HSHA臨床スコアはフルオキセチンの投与量（ピアソン相関、p<0.01）および投与期間（ピアソン相関、p<0.05）と相関していた。治療からの離脱が成功した犬は54％であった。

These results suggest that HSHA spectrum can range from mild clinical signs to widely pervasive and invalidating ones.

これらの結果は、HSHAのスペクトルが、軽度の臨床症状から、広く蔓延し無効となるものまで、さまざまであることを示唆している。

Starting the treatment as early as possible seems determinant for the welfare of the dog and for the dog-owner relationship, but doesn’t allow a shorter treatment (Kruskall-Wallis, p=0.84) or more chances for a weaning (Fisher’s exact test, p=0.88).

可能な限り早期に治療を開始することは、犬の福祉と犬と飼い主の関係を決定するようだが、治療期間を短縮したり（Kruskall-Wallis、p=0.84）、離乳の機会を増やすことはできない（Fisherの正確検定、p=0.88）。

However, high dose fluoxetine associated with behavioural modifications appear to be useful and well tolerated to treat this complex syndrome.

しかし、フルオキセチンの大量投与と行動修正との併用は、この複雑な症候群の治療に有用であり、忍容性も高いと思われる。

References：参考文献

  1. American Psychiatric Association, 2017. Diagnostic and Statistical Manual of Mental Disorders (DSM5). American Psychiatric Association, Arlington.
    URL: https://www.psychiatry.org/psychiatrists/practice/dsm.
  2. Barrickman, L., Noyes, R., Kuperman, S., Schumacher, E., Verda, M., 1991. Treatment of ADHD with fluoxetine: A preliminary trial. J. Am. Acad. Child Adolesc. Psychiatry. https://doi.org/10.1016/S0890-8567(10)80011-5.
  3. Beata, C., 2007. Comportement du chien et du chat: 20 cas cliniques, Editions Medcom, P65.
  4. Beata, C., 2017. Hyperactivity-hypersensitivity syndrome and dissociative syndrome, resident study day, in: 11th International Veterinary Behaviour Meeting ESVCE- IVBM Samorin.
  5. Boy, F., Evans, C.J., Edden, R.A.E., Lawrence, A.D., Singh, K.D., Husain, M., Sumner, P., 2011. Dorso-lateral prefrontal γ-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol. Psychiatry.
    https://doi.org/10.1016/j.biopsych.2011.05.030.
  6. Carlisi, C.O., Chantiluke, K., Norman, L., Christakou, A., Barrett, N., Giampietro, V., Brammer, M., Sim-mons, A., Rubia, K., 2016. The effects of acute fluoxetine administration on temporal discounting in youth with ADHD. Psychol. Med. https://doi.org/10.1017/S0033291715002731.
  7. Chantiluke, K., Barrett, N., Giampietro, V., Santosh, P., Brammer, M., Simmons, A., Murphy, D.G., Rubia, K., 2015. Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD. Psychopharmacology (Berl). https://doi.org/10.1007/s00213-014-3837-2.
  8. Col, R., Day, C., Phillips, C.J.C., 2016. An epidemiological analysis of dog behavior problems presented to an Australian behavior clinic, with associated risk factors. J. Vet. Behav. Clin. Appl. Res.
    https://doi.org/10.1016/j.jveb.2016.07.001.
  9. Dalley, J.W., Roiser, J.P., 2012. Review Dopamine , Serotonin and Impulsivity. Neuroscience. VOL. 215, P42-58.
    https://doi.org/10.1016/j.neuroscience.2012.03.065.
  10. Denenberg, S., 2015. Vet Med Today: Animal Behavior Case of the Month, JAVMA, Vol 246, N° 9, May 1, 2015.
  11. Dodman, N.H., Donnelly, R., Shuster, L., Mertens, P., Rand, W., Miczek, K., 1996. Use of fluoxetine to treat dominance aggression in dogs. J. Am. Vet. Med. Assoc.
  12. Dramard, V., 2007. Vade Mecum Pathologie du comportement du chien et du chat. Editions Medcom, P25.
  13. Fadel, F.R., Driscoll, P., Pilot, M., Wright, H., Zulch, H., Mills, D., 2016. Differences in Trait Impulsivity Indicate Diversification of Dog Breeds into Working and Show Lines. Sci. Rep.
    https://doi.org/10.1038/srep22162.
  14. Faraone, S. V, Sergeant, J., Gillberg, C., Biederman, J., 2003. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. https://doi.org/10.1176/ajp.2007.164.6.942.
  15. Fonseca, M.S., Murakami, M., Mainen, Z.F., 2015. Activation of dorsal raphe serotonergic neurons pro-motes waiting but is not reinforcing. Curr. Biol.  VOLUME 25, ISSUE 3, P306-315.
    https://doi.org/10.1016/j.cub.2014.12.002.
  16. Gainetdinov, R.R., Wetsel, W.C., Jones, S.R., Levin, E.D., Jaber, M., Caron, M.C., 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science (80-. ).Vol 283, Issue 5400, pp. 397-401.
    https://doi.org/10.1126/science.283.5400.397.
  17. Hejjas, K., Vas, J., Topal, J., Szantai, E., Ronai, Z., Szekely, A., Kubinyi, E., Horvath, Z., Sasvari-Szekely, M., Miklosi, A., 2007. Association of polymorphisms in the dopamine D4 receptor gene and the activi-ty-impulsivity endophenotype in dogs. Anim. Genet.Volume38, Issue6, December.
    https://doi.org/10.1111/j.1365-2052.2007.01657.x
  18. Hoogman, M., et al, 2017. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. The Lancet Psy-chiatry. Jun;4(6):436
    doi:10.1016/S2215-0366(17)30049-4.
  19. Ibáñez, M., Anzola, B., 2009. Use of fluoxetine, diazepam, and behavior modification as therapy for treat-ment of anxiety-related disorders in dogs. J. Vet. Behav. Clin. Appl. Res.
    https://doi.org/10.1016/j.jveb.2009.04.001.
  20. Irimajiri, M., Luescher, A.U., Douglass, G., Robertson-Plouch, C., Zimmermann, A., Hozak, R., 2009. Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs. J. Am. Vet. Med. Assoc. https://doi.org/10.2460/javma.235.6.705.
  21. Isherwood, S.N., Robbins, T.W., Nicholson, J.R., Dalley, J.W., Pekcec, A., 2017. Selective and interactive effects of D2receptor antagonism and positive allosteric mGluR4 modulation on waiting impulsivity. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.05.006.
  22. Ito, H., Nara, H., et al, 2004. Allele Frequency Distribution of the Canine Dopamine Receptor D4 Gene Exon III and I in 23 Breeds. J. Vet. Med. Sci. https://doi.org/10.1292/jvms.66.815.
  23. Kanner, A.M., 2016. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence. Epilepsy Behav. https://doi.org/10.1016/j.yebeh.2016.03.022.
  24. Landsberg, G.M., Hunthausen, W., L., A., 1997. Handbook of behaviour problems of the dog and cat. Handb. Behav. Probl. dog cat.
  25. Landsberg, G.M., Hunthausen, W., Ackerman, L. 2013. Behavior problems of the dog and cat. 3rd Edition, Saunders Ltd, p. 490.
  26. Lit, L., Schweitzer, J.B., Iosif, A.M., Oberbauer, A.M., 2010. Owner reports of attention, activity, and im-pulsivity in dogs: A replication study. Behav. Brain Funct. https://doi.org/10.1186/1744-9081-6-1.
  27. Luno, I., Rosado, B., Palacio, J., Villegas, A., Gonzalez-Martinez, A., Garcia-Belenguer, S., 2015. Hyperactivity in a Weimaraner dog. Dog Behavior, 3-2015, pp. 32-40;
    doi 10.4454/db.vli3.17.
  28. Marlois, N., 16 November 2013. Fluoxetine : retour d’expérience, Congrès “Les psychotropes”, Paris.
  29. Marlois, N., Mege, C., 2013. Le chien hyperactif : tout ce qui bouge n’est pas HSHA. PratiqueVet 48 : 220-22.
  30. Marlois, N., Beata, C., 2017. Polyuria/polydipsia associated with Hypersensitivity-Hyperactivity syndrome (Attention Deficit Hyperactivity Disorder) in a dog. A case report of a male French Shepherd dog (Beauceron). 2017, in: 11th International Veterinary Behaviour Meeting ESVCE- IVBM Samorin.
  31. Marston, L.C., Bennett, P.C., Coleman, G.J., 2004. What happens to shelter dogs? An analysis of data for 1 year from three Australian shelters. J. Appl. Anim. Welf. Sci. https://doi.org/10.1207/s15327604jaws0701_2.
  32. Mege, C., Beata, C., Beaumont-Graff, E., Diaz, C., Habran, T., Marlois, N., Muller, G., 2003. Pathologie comportementale du chien. Masson-AFVAC, Paris, France, pp. 137-143.
  33. Miller, E.M., 2014. Dopamine and Glutamate Dysfunction in a Rodent Model of Attention-Deficit / Hy-peractivity Disorder : Implications for Future Neuropharmacology. Diss. Abstr. Int. Sect. B Sci. Eng.
  34. NIH consensus statement, 2000. National Institutes of Health Consensus Development Conference State-ment: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J. Am. Acad. Child Adolesc. Psychiatry.
  35. Oades, R.D., 2007. Role of the serotonin system in ADHD: Treatment implications. Expert Rev. Neuroth-er.
    https://doi.org/10.1586/14737175.7.10.1357.
  36. Overall, K.L., Manual of Clinical Behavioral Medicine for Dogs and Cats, Kindle 11679-12017.
  37. Oyama, M.A., Citron, L., Shults, J., Cimino Brown, D., Serpell, J.A., Farrar, J.T., 2017. Measuring Quality of Life in Owners of Companion Dogs: Development and Validation of a Dog Owner-specific Quality of Life Questionnaire. Anthrozoos. Volume 30, 2017. https://doi.org/10.1080/08927936.2016.1228774.
  38. Pageat, P., 1998. Pathologie du comportement du chien. Editions du point Vétérinaire, Maison-Alfort. p.270-274.
  39. Pineda, S., Anzola, B., Olivares, A., Ibáñez, M., 2014. Fluoxetine combined with clorazepate dipotas-sium and behaviour modification for treatment of anxiety-related disorders in dogs. Vet. J.
    https://doi.org/10.1016/j.tvjl.2013.11.021.
  40. Piturru, P., 2014. [Methylphenidate use in dogs with attention deficit hyperactivity disorder (ADHD). A case report of a Weimaraner bitch]. Tierarztl.
  41. Prax. Ausg. K. Kleintiere. Heimtiere.Polanczyk, G., de Lima, M.S., Horta, B.L., Biederman, J., Rohde, L.A., 2007. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry. June 2007 Volume 164 Number 6.
    https://doi.org/10.1176/ajp.2007.164.6.942.
  42. Puurunen, J., Sulkama, S., Tiira, K., Araujo, C., Lehtonen, M., Hanhineva, K., Lohi, H., 2016. A non-tar-geted metabolite profiling pilot study suggests that tryptophan and lipid metabolisms are linked with ADHD-like behaviours in dogs. Behav. Brain Funct. https://doi.org/10.1186/s12993-016-0112-1.
  43. Ramtekkar, U.P., Reiersen, A.M., Todorov, A.A., Todd, R.D., 2010. Sex and Age Differences in Attention-Deficit/Hyperactivity Disorder Symptoms and Diagnoses: Implications for DSM-V and ICD-11. J. Am. Acad. Child Adolesc. Psychiatry. https://doi.org/10.1097/00004583-201003000-00005.
  44. Simpson, B.S., Landsberg, G.M., Reisner, I.R., Ciribassi, J.J., Horwitz, D., Houpt, K.A., Kroll, T.L., Lu-escher, A., Moffat, K.S., Douglass, G., Robertson-Plouch, C., Veenhuizen, M.F., Zimmerman, A., Clark, T.P., 2007. Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet. Ther.
  45. van der Staay, F.J., Arndt, S.S., Nordquist, R.E., 2009. Evaluation of animal models of neurobehavioral dis-orders. Behav. Brain Funct.
    https://doi.org/10.1186/1744-9081-5-11.
  46. Vas, J., Topál, J., Péch, É., Miklósi, Á., 2007. Measuring attention deficit and activity in dogs: A new application and validation of a human ADHD questionnaire. Appl. Anim. Behav. Sci.
    https://doi.org/10.1016/j.applanim.2006.03.017.
  47. Wright, H.F., Mills, D.S., Pollux, P.M.J., 2012. Behavioural and physiological correlates of impulsivity in the domestic dog (Canis familiaris). Physiol. Behav. https://doi.org/10.1016/j.physbeh.2011.09.019.
  48. Wright, H.F., Mills, D.S., Pollux, P.M.J., 2011. Development and Validation of a Psychometric Tool forAssessing Impulsivity in the Domestic Dog (Canis familiaris). Int. J. Comp. Psychol.
    https://doi.org/10.5811/westjem.2011.5.6700.
  49. Wynchank, D., Berk, M., 1998. Fluoxetine treatment of acral lick dermatitis in dogs: A placebo- controlled randomized double blind trial. Depress. Anxiety. https://doi.org/10.1002/(SICI)1520-6394(1998)8:1<21::AID-DA4>3.0.CO;2-8.
  50. Zanghi, B.M., Kerr, W., Gierer, J., de Rivera, C., Araujo, J.A., Milgram, N.W., 2013. Characterizing behav-ioral sleep using actigraphy in adult dogs of various ages fed once or twice daily. J. Vet. Behav. Clin. Appl. Res.
    https://doi.org/10.1016/j.jveb.2012.10.007.
  51. Ziv, G., 2017. The effects of using aversive training methods in dogs – A review. J. Vet. Behav. Clin. Appl. Res.
    https://doi.org/10.1016/j.jveb.2017.02.004.
Keywords:

dog, hyperactivity, impulsivity, hypersensitivity, hyperreactivity, fluoxetine, ADHD-like syndrome

Retrospective study on hypersensitivity-hyperactivity syndrome in dogs: long-term outcome of high dose fluoxetine treatment and proposal of a clinical score | Dog behavior

［2010］犬の注意力、活動性、衝動性に関する飼い主の報告：再現研究 前の記事 ［2020］フィンランドの愛犬1万3700頭における犬の不安症の有病率、合併症、犬種の違い 次の記事

関連記事